B-Cellular_component	0	13	Mitochondrial	Mitochondrial	JJ	B-NP
O	14	23	apoptosis	apoptosis	NN	I-NP
O	24	27	and	and	CC	I-NP
O	28	31	FAK	FAK	NN	I-NP
O	32	41	signaling	signaling	NN	I-NP
O	42	52	disruption	disruption	NN	I-NP
O	53	55	by	by	IN	B-PP
O	56	57	a	a	DT	B-NP
O	58	63	novel	novel	JJ	I-NP
O	64	71	histone	histone	NN	I-NP
O	72	83	deacetylase	deacetylase	NN	I-NP
O	84	93	inhibitor	inhibitor	NN	I-NP
O	93	94	,	,	,	O
O	95	99	HTPB	HTPB	NN	B-NP
O	99	100	,	,	,	O
O	101	103	in	in	IN	B-PP
B-Cancer	104	113	antitumor	antitumor	JJ	B-NP
O	114	117	and	and	CC	I-NP
O	118	132	antimetastatic	antimetastatic	JJ	I-NP
O	133	138	mouse	mouse	NN	I-NP
O	139	145	models	model	NNS	I-NP
O	145	146	.	.	.	O

O	148	158	BACKGROUND	BACKGROUND	NN	B-NP
O	158	159	:	:	:	O
O	160	168	Compound	Compound	NN	B-NP
O	169	178	targeting	target	VBG	B-VP
O	179	186	histone	histone	NN	B-NP
O	187	198	deacetylase	deacetylase	NN	I-NP
O	199	200	(	(	(	O
O	200	204	HDAC	HDAC	NN	B-NP
O	204	205	)	)	)	O
O	206	216	represents	represent	VBZ	B-VP
O	217	218	a	a	DT	B-NP
O	219	222	new	new	JJ	I-NP
O	223	226	era	era	NN	I-NP
O	227	229	in	in	IN	B-PP
O	230	239	molecular	molecular	JJ	B-NP
B-Cancer	240	246	cancer	cancer	NN	I-NP
O	247	259	therapeutics	therapeutic	NNS	I-NP
O	259	260	.	.	.	O

O	261	268	However	However	RB	B-ADVP
O	268	269	,	,	,	O
O	270	279	effective	effective	JJ	B-NP
O	280	284	HDAC	HDAC	NN	I-NP
O	285	295	inhibitors	inhibitor	NNS	I-NP
O	296	299	for	for	IN	B-PP
O	300	303	the	the	DT	B-NP
O	304	313	treatment	treatment	NN	I-NP
O	314	316	of	of	IN	B-PP
B-Cancer	317	322	solid	solid	JJ	B-NP
I-Cancer	323	329	tumors	tumor	NNS	I-NP
O	330	336	remain	remain	VBP	B-VP
O	337	339	to	to	TO	I-VP
O	340	342	be	be	VB	I-VP
O	343	352	developed	develop	VBN	I-VP
O	352	353	.	.	.	O

O	354	365	METHODOLOGY	METHODOLOGY	NN	B-NP
O	365	366	/	/	SYM	I-NP
O	366	375	PRINCIPAL	PRINCIPAL	NN	I-NP
O	376	384	FINDINGS	FINDINGS	NNS	I-NP
O	384	385	:	:	:	O
O	386	390	Here	Here	RB	B-ADVP
O	390	391	,	,	,	O
O	392	394	we	we	PRP	B-NP
O	395	402	propose	propose	VBP	B-VP
O	403	404	a	a	DT	B-NP
O	405	410	novel	novel	JJ	I-NP
O	411	415	HDAC	HDAC	NN	I-NP
O	416	425	inhibitor	inhibitor	NN	I-NP
O	425	426	,	,	,	O
O	427	428	N	N	NN	B-NP
O	428	429	-	-	HYPH	B-NP
O	429	436	Hydroxy	Hydroxy	NN	I-NP
O	436	437	-	-	HYPH	B-NP
O	437	438	4	4	CD	I-NP
O	438	439	-	-	HYPH	O
O	439	440	(	(	(	O
O	440	441	4	4	CD	B-NP
O	441	442	-	-	HYPH	I-NP
O	442	455	phenylbutyryl	phenylbutyryl	NN	I-NP
O	455	456	-	-	HYPH	I-NP
O	456	461	amino	amino	NN	I-NP
O	461	462	)	)	)	O
O	463	472	benzamide	benzamide	NN	B-NP
O	473	474	(	(	(	O
O	474	478	HTPB	HTPB	NN	B-NP
O	478	479	)	)	)	O
O	479	480	,	,	,	O
O	481	483	as	as	IN	B-PP
O	484	485	a	a	DT	B-NP
O	486	495	potential	potential	JJ	I-NP
O	496	512	chemotherapeutic	chemotherapeutic	JJ	I-NP
O	513	517	drug	drug	NN	I-NP
O	518	521	for	for	IN	B-PP
B-Cancer	522	527	solid	solid	JJ	B-NP
I-Cancer	528	534	tumors	tumor	NNS	I-NP
O	534	535	.	.	.	O

O	536	539	The	The	DT	B-NP
O	540	544	HDAC	HDAC	NN	I-NP
O	545	555	inhibition	inhibition	NN	I-NP
O	556	558	of	of	IN	B-PP
O	559	563	HTPB	HTPB	NN	B-NP
O	564	567	was	be	VBD	B-VP
O	568	577	confirmed	confirm	VBN	I-VP
O	578	583	using	use	VBG	B-VP
O	584	588	HDAC	HDAC	NN	B-NP
O	589	597	activity	activity	NN	I-NP
O	598	603	assay	assay	NN	I-NP
O	603	604	.	.	.	O

O	605	608	The	The	DT	B-NP
O	609	626	antiproliferative	antiproliferative	JJ	I-NP
O	627	630	and	and	CC	I-NP
O	631	635	anti	anti	AFX	I-NP
O	635	636	-	-	HYPH	I-NP
O	636	645	migratory	migratory	JJ	I-NP
O	646	656	mechanisms	mechanism	NNS	I-NP
O	657	659	of	of	IN	B-PP
O	660	664	HTPB	HTPB	NN	B-NP
O	665	669	were	be	VBD	B-VP
O	670	682	investigated	investigate	VBN	I-VP
O	683	685	by	by	IN	B-PP
B-Cell	686	690	cell	cell	NN	B-NP
O	691	704	proliferation	proliferation	NN	I-NP
O	704	705	,	,	,	O
O	706	710	flow	flow	NN	B-NP
O	711	720	cytometry	cytometry	NN	I-NP
O	720	721	,	,	,	O
O	722	725	DNA	DNA	NN	B-NP
O	726	732	ladder	ladder	NN	I-NP
O	732	733	,	,	,	O
O	734	741	caspase	caspase	NN	B-NP
O	742	750	activity	activity	NN	I-NP
O	750	751	,	,	,	O
O	752	755	Rho	Rho	NN	B-NP
O	756	764	activity	activity	NN	I-NP
O	764	765	,	,	,	O
O	766	767	F	F	NN	B-NP
O	767	768	-	-	HYPH	B-NP
O	768	773	actin	actin	NN	I-NP
O	774	788	polymerization	polymerization	NN	I-NP
O	788	789	,	,	,	O
O	790	793	and	and	CC	O
O	794	801	gelatin	gelatin	NN	B-NP
O	801	802	-	-	HYPH	O
O	802	812	zymography	zymography	NN	B-NP
O	813	816	for	for	IN	B-PP
O	817	823	matrix	matrix	NN	B-NP
O	824	842	metalloproteinases	metalloproteinas	NNS	I-NP
O	843	844	(	(	(	O
O	844	848	MMPs	MMP	NNS	B-NP
O	848	849	)	)	)	O
O	849	850	.	.	.	O

O	851	855	Mice	Mouse	NNS	B-NP
O	856	860	with	with	IN	B-PP
B-Cancer	861	866	tumor	tumor	NN	B-NP
I-Cancer	867	876	xenograft	xenograft	NN	I-NP
O	877	880	and	and	CC	O
O	881	893	experimental	experimental	JJ	B-NP
O	894	904	metastasis	metastasis	NN	I-NP
O	905	910	model	model	NN	I-NP
O	911	915	were	be	VBD	B-VP
O	916	920	used	use	VBN	I-VP
O	921	923	to	to	TO	B-VP
O	924	932	evaluate	evaluate	VB	I-VP
O	933	940	effects	effect	NNS	B-NP
O	941	943	on	on	IN	B-PP
B-Cancer	944	949	tumor	tumor	NN	B-NP
O	950	956	growth	growth	NN	I-NP
O	957	960	and	and	CC	I-NP
O	961	971	metastasis	metastasis	NN	I-NP
O	971	972	.	.	.	O

O	973	976	Our	Our	PRP$	B-NP
O	977	984	results	result	NNS	I-NP
O	985	994	indicated	indicate	VBD	B-VP
O	995	999	that	that	IN	B-SBAR
O	1000	1004	HTPB	HTPB	NN	B-NP
O	1005	1008	was	be	VBD	B-VP
O	1009	1010	a	a	DT	B-NP
O	1011	1014	pan	pan	NN	I-NP
O	1014	1015	-	-	HYPH	B-NP
O	1015	1019	HDAC	HDAC	NN	I-NP
O	1020	1029	inhibitor	inhibitor	NN	I-NP
O	1030	1032	in	in	IN	B-PP
O	1033	1044	suppressing	suppress	VBG	B-VP
B-Cell	1045	1049	cell	cell	NN	B-NP
O	1050	1059	viability	viability	NN	I-NP
O	1060	1072	specifically	specifically	RB	B-ADVP
O	1073	1075	of	of	IN	B-PP
B-Cell	1076	1080	lung	lung	NN	B-NP
I-Cell	1081	1087	cancer	cancer	NN	I-NP
I-Cell	1088	1093	cells	cell	NNS	I-NP
O	1094	1097	but	but	CC	B-PP
O	1098	1101	not	not	RB	B-NP
O	1102	1104	of	of	IN	B-PP
O	1105	1108	the	the	DT	B-NP
O	1109	1115	normal	normal	JJ	I-NP
B-Cell	1116	1120	lung	lung	NN	I-NP
I-Cell	1121	1126	cells	cell	NNS	I-NP
O	1126	1127	.	.	.	O

O	1128	1132	Upon	Upon	IN	B-PP
O	1133	1137	HTPB	HTPB	NN	B-NP
O	1138	1147	treatment	treatment	NN	I-NP
O	1147	1148	,	,	,	O
B-Cell	1149	1153	cell	cell	NN	B-NP
O	1154	1159	cycle	cycle	NN	I-NP
O	1160	1166	arrest	arrest	NN	I-NP
O	1167	1170	was	be	VBD	B-VP
O	1171	1178	induced	induce	VBN	I-VP
O	1179	1182	and	and	CC	O
O	1183	1195	subsequently	subsequently	RB	B-VP
O	1196	1199	led	lead	VBD	I-VP
O	1200	1202	to	to	TO	B-PP
B-Cellular_component	1203	1215	mitochondria	mitochondrion	NNS	B-NP
O	1215	1216	-	-	HYPH	O
O	1216	1224	mediated	mediate	VBN	B-NP
O	1225	1234	apoptosis	apoptosis	NN	I-NP
O	1234	1235	.	.	.	O

O	1236	1240	HTPB	HTPB	NN	B-NP
O	1241	1250	disrupted	disrupt	VBD	B-VP
O	1251	1252	F	F	NN	B-NP
O	1252	1253	-	-	HYPH	B-NP
O	1253	1258	actin	actin	NN	I-NP
O	1259	1267	dynamics	dynamic	NNS	I-NP
O	1268	1271	via	via	IN	B-PP
O	1272	1286	downregulating	downregulate	VBG	B-VP
O	1287	1291	RhoA	RhoA	NN	B-NP
O	1292	1300	activity	activity	NN	I-NP
O	1300	1301	.	.	.	O

O	1302	1310	Moreover	Moreover	RB	B-ADVP
O	1310	1311	,	,	,	O
O	1312	1316	HTPB	HTPB	NN	B-NP
O	1317	1326	inhibited	inhibit	VBD	B-VP
O	1327	1335	activity	activity	NN	B-NP
O	1336	1338	of	of	IN	B-PP
O	1339	1343	MMP2	MMP2	NN	B-NP
O	1344	1347	and	and	CC	I-NP
O	1348	1352	MMP9	MMP9	NN	I-NP
O	1352	1353	,	,	,	O
O	1354	1361	reduced	reduce	VBD	B-VP
O	1362	1370	integrin	integrin	NN	B-NP
O	1370	1371	-	-	HYPH	B-NP
O	1371	1376	beta1	beta1	NN	I-NP
O	1376	1377	/	/	SYM	I-NP
O	1377	1382	focal	focal	JJ	I-NP
O	1383	1391	adhesion	adhesion	NN	I-NP
O	1392	1399	complex	complex	NN	I-NP
O	1400	1409	formation	formation	NN	I-NP
O	1410	1413	and	and	CC	O
O	1414	1423	decreased	decrease	VBD	B-VP
B-Immaterial_anatomical_entity	1424	1436	pericellular	pericellular	JJ	B-NP
O	1437	1441	poly	poly	NN	I-NP
O	1441	1442	-	-	HYPH	B-NP
O	1442	1453	fibronectin	fibronectin	NN	I-NP
O	1454	1464	assemblies	assembly	NNS	I-NP
O	1464	1465	.	.	.	O

O	1466	1473	Finally	Finally	RB	B-ADVP
O	1473	1474	,	,	,	O
B-Immaterial_anatomical_entity	1475	1490	intraperitoneal	intraperitoneal	JJ	B-NP
O	1491	1500	injection	injection	NN	I-NP
O	1501	1503	or	or	CC	O
B-Organism_subdivision	1504	1508	oral	oral	JJ	B-NP
O	1509	1523	administration	administration	NN	I-NP
O	1524	1526	of	of	IN	B-PP
O	1527	1531	HTPB	HTPB	NN	B-NP
O	1532	1543	efficiently	efficiently	RB	B-ADVP
O	1544	1553	inhibited	inhibit	VBD	B-VP
B-Cancer	1554	1558	A549	A549	NN	B-NP
I-Cancer	1559	1568	xenograft	xenograft	NN	I-NP
I-Cancer	1569	1574	tumor	tumor	NN	I-NP
O	1575	1581	growth	growth	NN	I-NP
O	1582	1584	in	in	FW	B-ADVP
O	1585	1589	vivo	vivo	FW	I-ADVP
O	1590	1597	without	without	IN	B-PP
O	1598	1602	side	side	JJ	B-NP
O	1603	1610	effects	effect	NNS	I-NP
O	1610	1611	.	.	.	O

O	1612	1616	HTPB	HTPB	NN	B-NP
O	1617	1624	delayed	delay	VBD	B-VP
B-Organ	1625	1629	lung	lung	NN	B-NP
O	1630	1640	metastasis	metastasis	NN	I-NP
O	1641	1643	of	of	IN	B-PP
B-Cell	1644	1647	4T1	4T1	NN	B-NP
I-Cell	1648	1653	mouse	mouse	NN	I-NP
I-Cell	1654	1660	breast	breast	NN	I-NP
I-Cell	1661	1667	cancer	cancer	NN	I-NP
I-Cell	1668	1673	cells	cell	NNS	I-NP
O	1673	1674	.	.	.	O

O	1675	1686	Acetylation	Acetylation	NN	B-NP
O	1687	1689	of	of	IN	B-PP
O	1690	1697	histone	histone	NN	B-NP
O	1698	1701	and	and	CC	O
O	1702	1705	non	non	AFX	B-NP
O	1705	1706	-	-	HYPH	I-NP
O	1706	1713	histone	histone	NN	I-NP
O	1714	1722	proteins	protein	NNS	I-NP
O	1722	1723	,	,	,	O
O	1724	1733	induction	induction	NN	B-NP
O	1734	1736	of	of	IN	B-PP
O	1737	1746	apoptotic	apoptotic	JJ	B-NP
O	1746	1747	-	-	HYPH	I-NP
O	1747	1754	related	related	JJ	I-NP
O	1755	1763	proteins	protein	NNS	I-NP
O	1764	1767	and	and	CC	I-NP
O	1768	1770	de	de	NN	I-NP
O	1770	1771	-	-	HYPH	I-NP
O	1771	1786	phosphorylation	phosphorylation	NN	I-NP
O	1787	1789	of	of	IN	B-PP
O	1790	1795	focal	focal	JJ	B-NP
O	1796	1804	adhesion	adhesion	NN	I-NP
O	1805	1811	kinase	kinase	NN	I-NP
O	1812	1816	were	be	VBD	B-VP
O	1817	1826	confirmed	confirm	VBN	I-VP
O	1827	1829	in	in	IN	B-PP
O	1830	1837	treated	treat	VBN	B-NP
O	1838	1842	mice	mouse	NNS	I-NP
O	1842	1843	.	.	.	O

O	1844	1855	CONCLUSIONS	CONCLUSIONS	NNS	B-NP
O	1855	1856	/	/	SYM	B-NP
O	1856	1868	SIGNIFICANCE	SIGNIFICANCE	NN	I-NP
O	1868	1869	:	:	:	O
O	1870	1875	These	These	DT	B-NP
O	1876	1883	results	result	NNS	I-NP
O	1884	1893	suggested	suggest	VBD	B-VP
O	1894	1898	that	that	IN	B-SBAR
O	1899	1908	intrinsic	intrinsic	JJ	B-NP
O	1909	1918	apoptotic	apoptotic	JJ	I-NP
O	1919	1926	pathway	pathway	NN	I-NP
O	1927	1930	may	may	MD	B-VP
O	1931	1938	involve	involve	VB	I-VP
O	1939	1941	in	in	IN	B-PP
O	1942	1946	anti	anti	AFX	B-NP
O	1946	1947	-	-	HYPH	I-NP
B-Cancer	1947	1952	tumor	tumor	NN	I-NP
O	1953	1959	growth	growth	NN	I-NP
O	1960	1967	effects	effect	NNS	I-NP
O	1968	1970	of	of	IN	B-PP
O	1971	1975	HTPB	HTPB	NN	B-NP
O	1976	1978	in	in	IN	B-PP
B-Cell	1979	1983	lung	lung	NN	B-NP
I-Cell	1984	1990	cancer	cancer	NN	I-NP
I-Cell	1991	1996	cells	cell	NNS	I-NP
O	1996	1997	.	.	.	O

O	1998	2002	HTPB	HTPB	NN	B-NP
O	2003	2016	significantly	significantly	RB	B-VP
O	2017	2027	suppresses	suppress	VBZ	I-VP
B-Cancer	2028	2033	tumor	tumor	NN	B-NP
O	2034	2044	metastasis	metastasis	NN	I-NP
O	2045	2051	partly	partly	RB	B-ADVP
O	2052	2059	through	through	IN	B-PP
O	2060	2070	inhibition	inhibition	NN	B-NP
O	2071	2073	of	of	IN	B-PP
O	2074	2082	integrin	integrin	NN	B-NP
O	2082	2083	-	-	HYPH	B-NP
O	2083	2088	beta1	beta1	NN	I-NP
O	2088	2089	/	/	SYM	I-NP
O	2089	2092	FAK	FAK	NN	I-NP
O	2092	2093	/	/	SYM	B-NP
O	2093	2096	MMP	MMP	NN	I-NP
O	2096	2097	/	/	SYM	I-NP
O	2097	2101	RhoA	RhoA	NN	I-NP
O	2101	2102	/	/	SYM	B-NP
O	2102	2103	F	F	NN	I-NP
O	2103	2104	-	-	HYPH	B-NP
O	2104	2109	actin	actin	NN	I-NP
O	2110	2118	pathways	pathway	NNS	I-NP
O	2118	2119	.	.	.	O

O	2120	2122	We	We	PRP	B-NP
O	2123	2127	have	have	VBP	B-VP
O	2128	2136	provided	provide	VBN	I-VP
O	2137	2147	convincing	convince	VBG	I-VP
O	2148	2159	preclinical	preclinical	JJ	B-NP
O	2160	2168	evidence	evidence	NN	I-NP
O	2169	2173	that	that	IN	B-SBAR
O	2174	2178	HTPB	HTPB	NN	B-NP
O	2179	2181	is	be	VBZ	B-VP
O	2182	2183	a	a	DT	B-NP
O	2184	2190	potent	potent	JJ	I-NP
O	2191	2195	HDAC	HDAC	NN	I-NP
O	2196	2204	targeted	target	VBD	B-VP
O	2205	2214	inhibitor	inhibitor	NN	B-NP
O	2215	2218	and	and	CC	O
O	2219	2221	is	be	VBZ	B-VP
O	2222	2226	thus	thus	RB	B-ADVP
O	2227	2228	a	a	DT	B-NP
O	2229	2238	promising	promising	JJ	I-NP
O	2239	2248	candidate	candidate	NN	I-NP
O	2249	2252	for	for	IN	B-PP
B-Cancer	2253	2257	lung	lung	NN	B-NP
I-Cancer	2258	2264	cancer	cancer	NN	I-NP
O	2265	2277	chemotherapy	chemotherapy	NN	I-NP
O	2277	2278	.	.	.	O

